Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

  title={Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder},
  author={Thomas J. Spencer and Lenard A Adler and James J. McGough and Rafael Muniz and Hai Jiang and Linda K Pestreich},
  journal={Biological Psychiatry},

Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD

Once-daily d-MPH-ER 20 to 40 mg is safe and effective for long-term treatment of adult ADHD.

Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.

All three doses of d-MPH XR were significantly more effective than placebo in improving ADHD symptoms as confirmed by the teacher, parent and clinician and demonstrated a consistent safety profile.

Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study

Evaluating the efficacy and safety of SHP465 mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder (ADHD) found that the percentage of participants categorized as improved on Clinical Global Impressions-Improvement was higher with both SHP 465 MAS doses than with placebo (both nominal p < 0.001).

Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.

It is found little evidence that demographic factors, prior pharmacotherapy, the emergence of adverse events during the trial, or changes in ADHD symptoms from the screening to baseline assessments predicted placebo response.

Relationship of ADHD Symptoms and Global Illness Severity in Adults Treated with Lisdexamfetamine Dimesylate

Although ADHD symptom scores demonstrate a linear relationship with global illness severity, the variance suggests that other factors not captured by symptom scales are also important in assessing patient outcomes in clinical practice.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

MPH ER treatment in low to moderate doses was effective and safe in the treatment of ADHD in adults and the interpretation of the results is limited by the low dose-range used in this study, the high drop-out rate and placebo-response which might have affected the therapeutic effect size.

Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study

In a dose escalation ranging from 36 to 108 mg/d, OROS methylphenidate is effective and well tolerated in the management of ADHD in adults.

Clinical Effects of Lisdexamfetamine and Mixed Amphetamine Salts Immediate Release in Adult ADHD: Results of a Crossover Design Clinical Trial

In this crossover study, both LDX and MAS-IR had significant effects on ADHD clinician ratings and measures of executive function (with response rates of about 80%); patients in this monitored clinical trial were adherent with once dailyLDX and 3 times a dayMAS-IR, which may not be the case in real-world clinical practice.

Medication Adherence and Symptom Reduction in Adults Treated with Mixed Amphetamine Salts in a Randomized Crossover Study

Adult with ADHD adhered equally well with MAS IR as with MAS XR when assessed by pill count and self-report, but not by the MEMS® measures.

Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity

Overall, MPH is an effective ADHD treatment with a good safety profile and data suggest that dose optimization may enhance the safety and efficacy of treatment; further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD.



Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD

Treatment with MAS XR 20–60 mgl day for adult ADHD was generally well tolerated and was associated with sustained symptomatic improvement for up to 24 months.

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated, and these promising results provide support for further studies of tomoxettine over an extended period of treatment.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

In children with ADHD-CT, the most common subtype of ADHD, increasing doses of stimulant medication were associated with increased improvement of inattention and hyperactivity symptoms and less benefit was derived from higher doses.

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

Robust doses of methylphenidate are effective in the treatment of adult ADHD, independent of gender, psychiatric comorbidity with anxiety or moderate depression, or family history of psychiatric disorders.

Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder

Strong support is found for the assertion that MPH is efficacious for treating adult ADHD and provides further assurance to clinicians that the diagnosis of ADHD can be validly applied in adulthood.

An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD

In adults with ADHD, MAS XR treatment is generally safe and demonstrates significant improvement in ADHD symptoms and related quality of life.

A controlled study of Methylphenidate in the treatment of Attention Deficit Disorder, Residual Type, in Adults

The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.

Analog classroom assessment of Adderall in children with ADHD.

This documentation of efficacy in a controlled study supports the addition of Adderall to the armamentarium of psychotropic medications for the treatment of ADHD.

Attention-deficit/hyperactivity disorder: a life-span perspective.

  • J. Biederman
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1998
A variety of pharmacologic agents are available in treating ADHD: stimulant medications remain the first-line treatment for noncomorbid ADHD, whereas tricyclic antidepressants and bupropion are recommended for stimulant nonresponders and patients with more than one psychiatric disorder.